The appointment comes at a crucial time for Femasys as it seeks to expand its portfolio of fertility and non-surgical permanent birth control solutions. Canning's expertise in operational excellence is expected to strengthen the company's capabilities in commercializing its innovative products, including FemBloc and FemaSeed. Kathy Lee-Sepsick, Founder and CEO of Femasys, expressed confidence in Canning's ability to inform strategy through execution expertise, which is vital for the company's growth trajectory.
In conjunction with his appointment, Canning will receive an annual base salary of $450,000 and will be eligible for a target bonus of 40% of his base salary. Additionally, he will be granted a nonstatutory stock option to purchase 150,000 shares of Femasys common stock, which will vest over four years, aligning his interests with those of the company's shareholders. This employment agreement reflects Femasys's commitment to attracting top talent to drive its mission forward.
The company also issued a press release detailing Canning's appointment, highlighting his proven track record in the medical device sector and his readiness to lead Femasys into its next phase of growth. As Femasys continues to innovate in women's health, Canning's leadership is anticipated to play a pivotal role in enhancing operational execution and supporting the company's strategic objectives.
